Cargando…
Ultrarush immunotherapy with polymerized extracts during the coronavirus disease 2019 pandemic: Safety of restarting administrations without dose adjustments
Autores principales: | Bragança, Mariana, Plácido, José Luís, Amaral, Luís |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875858/ https://www.ncbi.nlm.nih.gov/pubmed/35227900 http://dx.doi.org/10.1016/j.anai.2022.02.014 |
Ejemplares similares
-
Ultrarush schedule of subcutaneous immunotherapy with modified allergen extracts is safe in paediatric age
por: Morais-Almeida, Mário, et al.
Publicado: (2016) -
Safety and Efficacy of Tree Pollen Specific Immunotherapy on the Ultrarush Administration Schedule Method Using Purethal Trees
por: Bozek, Andrzej, et al.
Publicado: (2014) -
Twelve-Hour Ultrarush Immunotherapy in a Patient With Mastocytosis and Hymenoptera Sting Anaphylaxis
por: Jäger, Doris, et al.
Publicado: (2009) -
Induction of Specific Immunotherapy with Hymenoptera Venoms Using Ultrarush Regimen in Children: Safety and Tolerance
por: Köhli-Wiesner, Alice, et al.
Publicado: (2012) -
Hymenoptera Venom Immunotherapy: Tolerance and Efficacy of an Ultrarush Protocol versus a Rush and a Slow Conventional Protocol
por: Patella, Vincenzo, et al.
Publicado: (2012)